Small-molecule targeted therapy (TT) has brought great hopes to patients with advanced malignancies. However, most patients suffer from tumor progression and relapse due to drug resistance. Recently, considerable efforts trying to elucidate the underlying mechanisms have focused on the contribution of cancer stem cells (CSCs) to the targeted therapy resistance (TTR). In this article, we provide an overview of the currently available literature on the rising roles of CSCs in TTR, as well as therapeutic opportunities of combining TT and anti-CSC therapy in the treatment of advanced malignancies.
Keywords: Anti-CSC therapy; Cancer stem cells; Combinational therapy; Targeted therapy; Targeted therapy resistance.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.